Iovance Biotherapeutics, Inc. logo

IOVA

Iovance Biotherapeutics, Inc.

$8.31

Earnings Summary

Revenue
$0.72Mn
Net Profits
$-112.98Mn
Net Profit Margins
-15800.84%

Highlights

Revenue:

Iovance Biotherapeutics, Inc.’s revenue jumped +Inf% since last year same period to $0.72Mn in the Q1 2024. On a quarterly growth basis, Iovance Biotherapeutics, Inc. has generated 48.34% jump in its revenue since last 3-months.

Net Profits:

Iovance Biotherapeutics, Inc.’s net profit fell -8.75% since last year same period to $-112.98Mn in the Q1 2024. On a quarterly growth basis, Iovance Biotherapeutics, Inc. has generated 2.92% jump in its net profits since last 3-months.

Net Profit Margins:

Iovance Biotherapeutics, Inc.’s net profit margin jumped NaN% since last year same period to -15800.84% in the Q1 2024. On a quarterly growth basis, Iovance Biotherapeutics, Inc. has generated 34.56% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Iovance Biotherapeutics, Inc. post its latest quarter earnings

EPS Estimate Current Year
-0.42

Highlights

EPS Estimate Current Year:

Iovance Biotherapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.42.

Key Ratios

Key ratios of the Iovance Biotherapeutics, Inc. post its Q1 2024 earnings

Earning Per Share (EPS)
-0.42
Return on Assets (ROA)
-0.34
Return on Equity (ROE)
-0.67

Highlights

Earning Per Share (EPS):

Iovance Biotherapeutics, Inc.’s earning per share (EPS) jumped 16% since last year same period to -0.42 in the Q1 2024. This indicates that the Iovance Biotherapeutics, Inc. has generated 16% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Iovance Biotherapeutics, Inc.’s return on assets (ROA) stands at -0.34.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Iovance Biotherapeutics, Inc.’s return on equity (ROE) stands at -0.67.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2024-05-09
-0.42
-0.42
0%

Discover More Earning Stocks in Health Technology Sector